Bio-Path Holdings is a biotechnology company focused on the development of innovative cancer therapies that utilize its proprietary DNA-based drug delivery platform
The company’s main objective is to create and advance treatments that enhance the effectiveness of existing cancer treatments while reducing side effects. By leveraging its proprietary technology, Bio-Path aims to deliver therapeutic agents directly to cancer cells, thereby improving treatment outcomes and addressing unmet medical needs in oncology. The company is committed to advancing its drug candidates through clinical trials and collaboration with research institutions to bring new hope to patients battling cancer.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease
Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here's what you need to know.
Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path...
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview.
